Goldman Called 2019 ‘The Year of NASH,’ Others Say Not So Fast

(Bloomberg) -- The fatty liver disease that some on Wall Street view as health care’s next blockbuster market may take another year or two to develop, according to analysts.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.